Breadcrumb

  1. Perspectives
  2. Alerts

Alerts

1114 total results. Page 1 of 45.

With only two months until the January 1 implementation of the final State Cannabis Regulations, the California agencies given licensing authority under the Medicinal and Adult-use Cannabis Regulation and Safety Act posted last minute changes that are causing quite a buzz in the cannabis community. 
This August, Ohio became the first state in the nation to pass a law incentivizing organizations to develop a strong data protection and cybersecurity program.
The FDA has delayed the date on which it plans to enforce compliance with certain Unique Device Identification (UDI) requirements, prompting a concerted sigh of relief throughout the medical device community. 
Late last month, in Daniels v. Fan Duel, Inc., et ano, the Indiana Supreme Court sided with the fantasy sports industry holding that the use of the names, pictures, and statistics of athletes by online-fantasy sports operators without the athletes’ consent does not violate the right of publicity.
As the dust settles on a campaign cycle that was unprecedented in many ways, we have composed this biennial post-election analysis to assist our clients in assessing the potential impact of the elections on their organizations and their industries.
Below is a roundup of headlines that matter and key takeaways from the industries and issues we're following closely. We'll be back later today with more in-depth analysis.
As class action practitioners know, class certification can be difficult to achieve, particularly in the years since the Supreme Court’s decision in Wal-Mart Stores, Inc. v. Dukes. 
Back in May 2018, President Trump announced the United States’ intention to withdraw from the Joint Comprehensive Plan of Action (JCPOA) and re-impose secondary sanctions on Iran. 
The Government of Australia is proposing a new bill that would grant additional powers to law enforcement and national security agencies.
Colorado’s new consumer data protection law, the Protections for Consumer Data Privacy Act, took effect September 1 and companies now have another set of requirements to comply with for their data privacy compliance.
The Food and Drug Administration is maintaining its August 2017 commitment to step up enforcement against violative stem cell therapy and regenerative medicine companies. But FDA’s activity hasn’t stopped the Federal Trade Commission from flexing its own regulatory muscle against the same industry.
If the turbulence of 2018 caused business executives grief, the year ahead is unlikely to provide much relief.  Foremost is the United States-Mexico-Canada Agreement (USMCA). If most political pundits are correct, the three governments will likely be able to ratify the USMCA in time to be in full fo
On October 11, the United States Patent and Trademark Office published a new final rule altering the claim construction standard applied in inter partes review, post grant review, and covered business method review proceedings.
On October 17, 2018, Canada celebrated Legalization Day – an event marking the end of a prohibition against recreational cannabis use. 
Efforts to update FDA’s personal care products regulations continue as Rep. Jan Schakowsky (D-IL) recently introduced H.R. 6903, the “Safe Cosmetics and Personal Care Products Act of 2018.” 
Last week, CPSC announced that Costco Wholesale, Corp., of Issaquah, WA, had agreed to pay a $3.85 million civil penalty for failing to report to the Commission that the EKO Sensible Eco Living Trash Cans sold by Costco contained a defect that created an unreasonable risk of serious injury.
Last week, the FDA confirmed it conducted a surprise inspection of e-cigarette manufacture Juul Labs. 
On October 1, 2018, the New York State Department of Labor announced its final regulations to prevent workplace harassment.
In the last hour of the last day of last month, with 30 minutes to spare, US Trade Representative Lighthizer met the US self-imposed deadline and formally sent to Congress the agreed-upon text of a US-Mexico-Canada Agreement, or USMCA.
Last week, the Drug Enforcement Agency (DEA) published in the Federal Register its Final Order placing FDA-approved cannabidiol drug products (CBD) containing no more than 0.1 percent tetrahydrocannabinols in schedule V of the Controlled Substances Act. 
US Customs and Border Protection’s Executive Assistant Commissioner of Field Operations, Todd Owen, recently spoke with Politico and confirmed that CBP will continue to apply long-standing US federal laws and regulations that treat marijuana as a banned substance at the US border. 
Cardiologists are being challenged to find ways to incorporate data from a new OTC mobile medical app into their practices and patient interactions. As wearable technology becomes increasingly medical, this dynamic may represent a harbinger of future health management obstacles.
The Trump Administration recently announced several major decisions, including: finalizing the List 3 products subject to additional duties and revealing its implementation schedule.
The National Labor Relations Board (NLRB or Board) published a Notice of Proposed Rulemaking in the Federal Register on September 14, 2018 regarding its controversial joint-employer standard.